Brittany Lovely

Managing Editor, OncLive®
Brittany Lovely is a managing editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: blovely@mjhassoc.com

Articles

Progress in Disease Detection Sets the Stage for MRD’s Role in AML

February 27th 2023

For patients with acute myeloid leukemia, advances in targeting minimal residual disease represents the next wave of advances in the field and is necessary to cure this disease.

Liquid Biopsies and NGS Stand to Revolutionize Hematologic Malignancies

February 24th 2023

Andrew Ip, MD, delivers a keynote on the role for liquid biopsy and NGS in hematologic malignancies, including the barriers to implementing seamlessly into clinical practice.

Old Standards Are Revisited in HER2+ Early-Stage Breast Cancer

February 23rd 2023

As targeted agents for various levels of HER2 expression have demonstrated dynamic interoperability and efficacy, the prognosis for HER2-positive disease has improved.

Key Factors to Consider in the Management of Tumor Lysis Syndrome

February 22nd 2023

For patients with aggressive malignant tumors and high tumor burden, onco- logic emergencies such as tumor lysis syndrome emerge as a disease symptom or a treat- ment-related adverse effect.

Abiraterone/Olaparib Benefit Is Sustained in Final OS Analysis for mCRPC

February 16th 2023

The final prespecified overall survival analysis of PROpel showed that the combination of abiraterone acetate plus olaparib sustained a trend toward improved efficacy vs standard-of-care abiraterone in patients with metastatic castration-resistant prostate cancer.

Ponatinib Plus Reduced-Intensity Chemotherapy Steps Up as Potential New SOC in Newly Diagnosed Ph+ ALL

February 15th 2023

The primary end point of the phase 3 PhALLCON study was met as first-line ponatinib plus reduced-intensity chemotherapy outperformed imatinib for the treatment of patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

MOUNTAINEER-03 Propels Progress in Metastatic HER2+ CRC

February 3rd 2023

The MOUNTAINEER-03 trial is designed to evaluate the efficacy of tucatinib and trastuzumab plus modified leucovorin calcium, fluorouracil, and oxaliplatin, compared with standard-of-care, first-line therapy for metastatic HER2-positive colorectal cancer.

Modest Clinical Benefit Is Observed With or Without Bevacizumab Added to Atezolizumab/Chemotherapy in BTC Signal Seeking Study

January 21st 2023

Treatment with or without bevacizumab added to atezolizumab plus cisplatin/gemcitabine demonstrated a modest clinical benefit for patients with advanced biliary tract cancer.

Treatment Complexities Continue to Mount in Gynecologic Cancers

January 3rd 2023

Data concerning the long-term benefit of PARP inhibitors as maintenance therapy for select patients with ovarian cancer in later-line settings have come under fire in 2022 as several agents have failed to demonstrate improvements in OS outcomes.

Prior Authorization Hurdles Delay Oncology Care

December 27th 2022

Prior authorization on cancer treatments is delaying patient care, affecting outcomes, and diverting providers from patient care according to results of a survey conducted by the Association for Clinical Oncology.

DESTINY-Breast04 Subgroup Analysis Confirms Trastuzumab Deruxtecan Benefit in HER2-low Metastatic Breast Cancer

December 26th 2022

Patient history and disease characteristics did not affect outcomes for patients with metastatic HER2-low breast cancer who received fam-trastuzumab deruxtecan-nxki in the DESTINY-Breast04 study.

Real-World Data Consistent With Patient-Reported Outcomes Regarding Axi-Cel Administration in Relapsed/Refractory LBCL

December 11th 2022

Patients receiving axicabtagene ciloleucel reported a temporary reduction in quality of life, followed by statistically significant improvements in overall QOL and symptoms within the first year of treatment for relapsed/refractory large B-cell lymphoma.

Neoadjuvant Olaparib Combo Fails to Surpass Carboplatin/Paclitaxel in HER2– Early Breast Cancer

December 9th 2022

Long-term clinical data failed to show a benefit of neoadjuvant olaparib (Lynparza) plus paclitaxel vs carboplatin plus paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer

December 7th 2022

A clinically meaningful improvement in invasive disease-free survival and distant relapse-free survival was observed with the addition of adjuvant abemaciclib to endocrine therapy in patients with hormone receptor–positive, HER2-negative, node-positive early breast cancer, according to results of a prespecified overall survival analysis of the monarchE study.

Prominence of HER2 Alterations in NSCLC Trigger Questions About Best Practices

December 6th 2022

As new classes of agents deliver promising results for patients with HER2-mutant non–small cell lung cancer, new questions surrounding optimal identification tactics, sequencing, and treatment of patients arise.

MRD Detection Emerges as a Catalyst for Advances in Colon Cancer

December 5th 2022

For patients with colon cancer, traditional clinical and pathologic risk factors may soon take a backseat as stratification tactics for determining optimal candidates for adjuvant chemotherapy.

Perspectives From the Frontline: What Is Happening on the Ground With NGS Testing in NSCLC?

November 28th 2022

Benjamin P. Levy, MD; Bhuvana Ramkumar, MD; and Neil Morganstein, MD, discuss the challenges with tissue testing facing care teams, as well as multilevel hurdles in procurement, analysis of results, and insurance.

HARMONIC Evaluates Novel Combination in Growing Population of Never Smokers With Advanced Lung Cancer

November 22nd 2022

In combination with standard-of-care carboplatin and pemetrexed, the investigational agent LP-300 will be evaluated in never smokers with non–small cell lung cancer in the phase 2 HARMONIC study.

Basket Trial Investigates Nab-Sirolimus for Treatment of TSC1/2 Mutations

November 14th 2022

With no approved agents for patients with malignant tumors harboring TSC1 or TSC2 inactivating alterations, investigators seek to establish a new pathway forward for patients with solid tumors in the PRECISION 1 trial.

Rugo Highlights Key Priorities for the Future of Breast Cancer Research

November 10th 2022

Research in breast cancer has led to remarkable progress in the understanding and management of the disease, but the oncology community can always do more to optimize treatment outcomes for patients.